2024: A year of achievements and progress

Our performance in 2024 confirmed that our strategic initiatives are paying off, with significant advancements and robust financial growth across all three therapeutic areas: Oncology, Rare Disease and Neuroscience. We reported strong financial growth, with total sales growth of 9.9% at constant exchange rate, across all three therapy areas. With four regulatory approvals in 2024 in Oncology and Rare Disease, our portfolio continued to expand. To fuel our pipeline, we closed six new external innovation deals. 

We made notable advances in our sustainability commitments, reducing our carbon footprint by 45% in Scope 1 and 2 emissions, and we continued to cultivate a global and inclusive culture.

See what CEO David Loew has to say about our 2024 performance.

The accomplishments of 2024 provide a solid foundation for future innovations and advancements. With much more to come in 2025, we are ready to build on this year’s success as we Focus. Together. For patients and society.